Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.

Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, Dickson ER, Lindor KD.

Hepatology. 1999 Jan;29(1):21-6.

PMID:
9862844
2.

Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.

Boberg KM, Wisløff T, Kjøllesdal KS, Støvring H, Kristiansen IS.

Aliment Pharmacol Ther. 2013 Oct;38(7):794-803. doi: 10.1111/apt.12435. Epub 2013 Aug 5.

3.

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.

Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE.

Hepatology. 1999 Jan;29(1):39-43.

PMID:
9862847
4.

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.

Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, Dickson ER.

Liver. 1999 Apr;19(2):115-21.

PMID:
10220741
5.

Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.

Heathcote EJ, Stone J, Cauch-Dudek K, Poupon R, Chazouilleres O, Lindor KD, Petz J, Dickson ER, Poupon RE.

Liver Transpl Surg. 1999 Jul;5(4):269-74.

6.

Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.

Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C, Villa E, Podda M.

Aliment Pharmacol Ther. 2001 Sep;15(9):1427-34.

7.

Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.

Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH.

Liver Transpl. 2007 Sep;13(9):1236-45.

8.

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.

Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES.

Hepatology. 1996 Nov;24(5):1098-103.

PMID:
8903382
9.

Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.

Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF.

Am J Gastroenterol. 2006 Jul;101(7):1529-38.

PMID:
16863557
10.

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.

Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD.

Hepatology. 1999 Mar;29(3):644-7.

PMID:
10051462
11.

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.

Parés A, Caballería L, Rodés J, Bruguera M, Rodrigo L, García-Plaza A, Berenguer J, Rodríguez-Martínez D, Mercader J, Velicia R.

J Hepatol. 2000 Apr;32(4):561-6.

PMID:
10782903
12.
13.

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.

Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, Scheuer PJ, Davies SE, Craxì A.

Aliment Pharmacol Ther. 2000 Dec;14(12):1645-52.

14.

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.

Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, et al.

Gastroenterology. 1994 May;106(5):1284-90.

PMID:
8174890
15.

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.

Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Rydén BO, Einarsson K, Lindgren S, Wallerstedt S, Wedén M.

Scand J Gastroenterol. 1997 Feb;32(2):179-86.

PMID:
9051880
16.

An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.

Neuman MG, Cameron RG, Haber JA, Katz GG, Blendis LM.

Liver. 2002 Jun;22(3):235-44.

PMID:
12100574
17.

[Treatment of cholestatic liver diseases with ursodeoxycholic acid].

Boberg KM, Schrumpf E.

Tidsskr Nor Laegeforen. 1997 Sep 30;117(23):3370-3. Review. Norwegian.

PMID:
9411890
18.

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, Happ J, Leuschner U.

Gastroenterology. 1999 Oct;117(4):918-25.

PMID:
10500075
19.

Ursodeoxycholic acid for primary biliary cirrhosis.

Gluud C, Christensen E.

Cochrane Database Syst Rev. 2002;(1):CD000551. Review. Update in: Cochrane Database Syst Rev. 2008;(3):CD000551.

PMID:
11869580
20.

Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.

Batts KP, Jorgensen RA, Dickson ER, Lindor KD.

Am J Gastroenterol. 1996 Nov;91(11):2314-7.

PMID:
8931409
Items per page

Supplemental Content

Write to the Help Desk